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On Genome-wide Association Studies for Family-Based
Designs: An Integrative Analysis Approach Combining
Ascertained Family Samples with Unselected Controls
Jessica Lasky-Su,1,2,* Sungho Won,3,4 Eric Mick,5 Richard J.L. Anney,6 Barbara Franke,7
Benjamin Neale,8,9 Joseph Biederman,5 Susan L. Smalley,10 Sandra K. Loo,10 Alexandre Todorov,11
Stephen V. Faraone,12 Scott T. Weiss,1,2 and Christoph Lange1,2,13
Large numbers of control individuals with genome-wide genotype data are now available through various databases. These controls are
regularly used in case-control genome-wide association studies (GWAS) to increase the statistical power. Controls are often ‘‘unselected’’
for the disease of interest and are not matched to cases in terms of confounding factors, making the studies more vulnerable to con-
founding as a result of population stratiﬁcation. In this communication, we demonstrate that family-based designs can integrate unse-
lected controls from other studies into the analysis without compromising the robustness of family-based designs against genetic con-
founding. The result is a hybrid case-control family-based analysis that achieves higher power levels than population-based studies with
the same number of cases and controls. This strategy is widely applicable and works ideally for all situations in which both family and
case-control data are available. The approach consists of three steps. First, we perform a standard family-based association test that does
not utilize the between-family component. Second, we use the between-family information in conjunction with the genotypes from
unselected controls in a Cochran-Armitage trend test. The p values from this step are then calculated by rank ordering the individual
Cochran-Armitage trend test statistics for the genotype markers. Third, we generate a combined p value with the association p values
from the ﬁrst two steps. Simulation studies are used to assess the achievable power levels of this method compared to standard analysis
approaches.We illustrate the approach by an application to a GWAS of attention deﬁcit hyperactivity disorder parent-offspring trios and
publicly available controls.With the advent of high-throughput genotyping, genome-
wide association studies (GWAS) are ubiquitous, and the
number of SNPs used in these studies continues to
increase. Through this genotyping breakthrough, genetic
variants have been identiﬁed and reliably replicated for
several complex diseases.1–6 Despite these successes, there
are still several factors that limit our current ability to
more readily identify disease variants, including insufﬁ-
cient statistical power, population stratiﬁcation, various
forms of between-study heterogeneity, ascertainment
schema, environmental inﬂuences, and time-varying asso-
ciations.7 There is no doubt that the ﬁeld of genetic epide-
miology as a whole has overestimated the genetic con-
tribution of common genetic variants. Given these
drawbacks, it is therefore essential to fully maximize the
sample size and the power of the analysis strategy that is
used.
Although family-based designs offer the advantage of
complete robustness against genetic heterogeneity, this
feature comes at the price of reduced statistical power
when compared with designs that are based on unrelated
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between-family component and a within-family compo-
nent. Because the between-family component is biased in
the presence of population substructure, family-based
association tests (FBATs) have utilized the within-family
component for the construction of the association test.8,9
In this communication, we develop a new overall FBAT
for ascertained samples that integrates unselected, geno-
typed controls from a population-based study into an over-
all statistical test. This statistical test has broad applica-
tions, because it can be applied to any situation in which
family data and case-control data are available. The new
overall test is more powerful than case-control studies
with the same number of cases and unselected controls,
while, at the same time, it is still completely robust against
population substructures.
As more GWAS data are produced, their control geno-
types often become readily available both from publicly
available sources (e.g., dbGaP10) and from commercial
companies (e.g., Affymetrix, Illumina, and Perlegen).
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utilize these samples in the analysis of family-based GWAS,
our method will increase the statistical power of existing
studies while not sacriﬁcing any of the robustness proper-
ties of the family design. This testing strategy is available
for use in the PBAT suite of analysis tools.11
Suppose that n independent parent-offspring trios are
sampled and genotyped at s biallelic marker loci with
alleles A and B. The genotype of the ith proband is denoted
by Xi. The parental genotypes in the i
th family are also
available and are denoted by pi1 and pi2. If the parental
information is missing, the proposed methodology can
be extended by replacing the parental genotype informa-
tion, pi1 and pi2, with the sufﬁcient statistic proposed by
Rabinowitz and Laird.9 Further, we assume that the trio
sample is fully ascertained, i.e., all offspring are affected.
The analysis of the family data set is now supplemented
by the integration ofm controls that have been genotyped
at the same s loci as the family sample. These controls may
be ‘‘selected’’ or ‘‘unselected’’ for the disease of interest.
If the controls are unselected for the disease of interest,
then individuals will have the disease at the rate prevalent
in the population. In contrast, selected controls are specif-
ically chosen to be free of the disease of interest. For most
practical purposes, unselected controls are more likely to
be available, because the publicly available databases are
not selected to exclude any given disease.
Similar to the approaches by VanSteen,12 Ionita,13
Murphy,14 and Won,15 we assessed the evidence of associ-
ation for each marker locus at a population-based level
(i.e., between-family level) and at a within-family level
by two statistics that are statistically independent. In order
to maintain the original robustness of the family design,
we used the transmission disequilibrium test (TDT)8/
FBAT9 to assess the information about the association at
a within-family level. Because the TDT/FBAT approach is
a conditional test that conditions on the offsprings’
phenotype and the parental genotype information, this
information, i.e., offsprings’ phenotypes and parental
genotypes, in addition to the data on the unselected con-
trols, can be used to construct a measure for association
at a population-based level that is statistically indepen-
dent of the TDT/FBAT statistic.16 Consequently, for each
marker, we assessed the evidence for association at the
population level by constructing a Cochran-Armitage
(C-A) trend test with a 2 3 3 table. In this table, the geno-
type distribution for the controls is deﬁned by the unse-
lected set of controls that are not part of the family study
but are available for the analysis. The genotype distribu-
tion for the cases in this table is derived based on the avail-
able and/or allowable data from the family study (i.e.,
offspring phenotypes and the parental genotypes, also
known as the between-family information) in addition to
the genotype information from any singleton cases that
were not used in the TDT/FBAT. As suggested in the condi-
tional mean model approach,16 we calculated the geno-
types of the affected offspring based on Mendelian trans-
mission from the parents, i.e., E(Xjpi1, pi2), and derived574 The American Journal of Human Genetics 86, 573–580, April 9, 2the genotype distribution for the cases in the 2 3 3 table
based on these calculated genotypes in the offspring gener-
ation. If the family sample contained additional unaffected
siblings, their imputed genotype could be used to enrich
the control distribution. Similarly, if there were additional
genotypes from individual cases that were not a part of any
family, then this genotype information could be included
in the C-A trend test. Although we propose a strategy in
which the C-A trend test is used in the second stage, this
general technique is ﬂexible and can easily be extended
to implement other statistical tests in the second stage
for case-control data (e.g., a two degree of freedom test).
Similarly, any genetic model can be incorporated into the
proposed analytic approach.
In this way, we can now construct the population-based
component of the overall test for each SNP by computing
a C-A trend test statistic for a 23 3 table, which is based on
the unselected controls and the imputed genotypes for the
cases (plus any additional singleton cases). In order to
retain the robustness of the original FBAT against popula-
tion admixture, the p values of the C-A are not obtained
on the basis of asymptotic distribution theory but on the
basis of the rank of the C-A statistic among the s marker
loci. To the ith ranked SNP based on the C-A statistic, we
assign the rank-based p value of pTi ¼ ði 0:5Þ=s. The
value 0.5 is a tuning parameter. The primary purpose of
the tuning parameter is to protect against population strat-
iﬁcation and maximize the statistical power. Methodolog-
ical work shows that a tuning parameter of 0.5 will always
ensure robustness against population stratiﬁcation. The
normal score statistic that corresponds to the p value pTi
is denoted by Z(T)i, where Z(T)i is normally distributed
with mean 0 and variance 1.
The within-family component is assessed with the clas-
sical TDT statistic8 or, if parents are missing and multiple
affected and unaffected offspring are available, with the
FBAT statistic.9 For the ith marker locus, we denote the p
value of the FBATstatistic by p(FBATi) and the standardized
normal score that reﬂects the p value by Z(FBATi). The
overall test integrating the within-family component, the
between-family component, and the unselected controls
can now be constructed via the weighted Z approach.17
Zi ¼ 1=
ﬃﬃﬃ
2
p
ZðFBATiÞ þ 1=
ﬃﬃﬃ
2
p
ZðTiÞ
It is straightforward to see that the overall association
tests are normally distributed with mean 0 and variance
1. Via the same arguments as in Won et al.,15 it is apparent
that the rank-based p values in the overall test statistic Zi
will ensure robustness against population admixture and
stratiﬁcation. For the analytical proof of this property, see
Won et al.15 Intuitively, the population robustness is
achieved by the fact that the population-based test statistic
T uses a rank-based p value. A rank-based p value can never
achieve genome-wide signiﬁcance by itself because it is
always greater than the Bonferroni adjusted signiﬁcance
level, i.e., 1/number of markers > 0.05/number of markers.010
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Figure 1. Power Simulations Comparing
the Method Proposed Here to the Stan-
dard TDT and Case-Control Analyses
while Using Unselected Controls
This ﬁgure depicts the results of power
simulations in which we used 3000 pro-
bands and compared the standard TDT
and case-control methods to the new
screening method we propose in this
manuscript. In this example, we assume
that the control individuals are unselected
for the disease of interest and that there is
a 1:1 matching of cases to control individ-
uals. By using unselected controls, we
assume that there are cases in the control
sample at the rate equal to the prevalence
of disease in the population.Therefore, because the overall test statistic Zi can only
establish genome-wide signiﬁcance through the within-
family component (FBATi), Zi is inherently robust against
population stratiﬁcation in the same manner that FBATs
are robust to population stratiﬁcation.
Because the unselected controls that are integrated in
the overall family-based association statistic will be from
a different study than the family sample, the presence of
potentially strong population stratiﬁcation is very likely.
Although, as discussed above, the overall test will not be
biased in the presence of such substructures, stratiﬁcation
between the unselected controls and the family study
poses the danger of reducing the overall statistical power,
which would eliminate the beneﬁt of including the unse-
lected controls in the analysis. It is therefore recommended
to apply population-based adjustment methods18,19 to the
population-based data, i.e., unselected controls and
imputed genotypes, to eliminate such effects and achieve
the maximal statistical power.
We performed simulations to evaluate the power of
the proposed methodology compared with other method-
ologies commonly in use. We assumed a 1,000,000 SNP
GWAS analysis that was adjusted for multiple comparisons
via the standard Bonferroni correction. When comparing
the different methodologies, we kept the total number of
probands equal to 3000 (i.e., 3000 parent-offspring trios
and 3000 case-control pairs) for all analysis methods.
We conducted simulations with minor allele frequencies
(MAFs) ranging from 10% to 40%. We assumed a genetic
effect size, measured as an odds ratio, of 1.3 and assumed
a disease prevalence of 5% and 10%. Because of the similar
ﬁndings, we only present the simulation results for
a disease prevalence of 5%. We compared the power of
a standard FBAT and a standard case-control analysis to
the proposed testing methodology with both unselected
and selected control individuals. We also compared the
power of the proposed testing strategy via a 1:1 and 1:2The Amratio of cases to controls. For each power estimate, we per-
formed 10,000 replicate analyses.
Figure 1 and Figure 2 show the power over a range of
MAFs. From these simulations, we see that the power esti-
mates of the new methodology (‘‘New screen’’) via a 1:1
ratio of unselected controls to cases is noticeably more
powerful than the standard TDT or a standard case-control
analysis. Surprisingly, the power for the TDT and the stan-
dard case-control analysis is similar, and through addi-
tional simulations (data not shown) we found that as the
disease prevalence in the population increases (and there-
fore the number of misclassiﬁed individuals in the unse-
lected control sample increases), the power of the new
screeningmethod can become even greater than the power
for the case-control analysis at speciﬁc MAFs. This already
happens if the disease prevalence is as small as 10% (data
not shown). Figure 1 illustrates the consistent and robust
power of our proposed screening method in comparison
with either of these default analyses, with increases in
power ranging between 10% and 20%.
If the number of unselected controls is increased to a 1:2
matching ratio, the standard case-control analysis has
increased power compared to the TDT, as shown in Fig-
ure 2. This ﬁgure also illustrates that the proposedmethod-
ology consistently remains the highest powered of the
three analysis methods.
In some cases, it is possible to obtain a control group that
is selected for the disease of interest, meaning that all indi-
viduals in the control group are known to not have the
disease being studied. Figure 3 shows that, in case of 1:1
case-control matching with selected controls, the new
testing strategy substantially outperforms both the TDT
and the case-control analysis. Comparable to the situation,
as shown in Figure 4, with unselected controls, if the
matching is increased to a ratio of two controls for every
case, the proposed methodology still outperforms the
other two methods but is only marginally better thanerican Journal of Human Genetics 86, 573–580, April 9, 2010 575
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Figure 2. Power Simulations Comparing
the Method Proposed Here to Standard
TDT and Case-Control Analyses with
a 1:2 Ratio of Cases to Unselected
Controls
This ﬁgure depicts the results of power
simulations in which we used 3000
probands and compared the standard
TDT and case-control methods to the
new screening method we propose in this
manuscript. In this example, we assume
that the control individuals are unselected
for the disease of interest and that there is
a 1:2 matching of cases to control individ-
uals. By using unselected controls, we
assume that there are cases in the control
sample at the rate equal to the prevalence
of disease in the population.a standard case-control design. However, one has to bear in
mind that this approach still has the additional beneﬁt of
being much less susceptible to population stratiﬁcation,
given that a family-based analysis is incorporated into
the test statistic.
We assessed the type I error for our simulations with an
overall alpha level of 0.05 and 100,000 replicates. After per-
forming this simulation eight different times, the type 1
error rates ranged from 0.495 to 0.0506, indicating that
the type I error rate for the proposed methodology was
extremely close to what we would expect.
We applied these data to families that were collected by
the International Multicenter ADHD Genetics (IMAGE)
project. Families were identiﬁed through attention deﬁcit
hyperactivity disorder (ADHD) (MIM 143465) probands
aged 5 to 17 attending outpatient clinics at the data collec-
tion sites in Europe. A total of 958 affected proband-parent0
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576 The American Journal of Human Genetics 86, 573–580, April 9, 2trios were initially selected for the GWAS scan (accession
number phs000016.v1.p1). Family members were white,
of European origin from seven countries around Europe,
including Belgium, Germany, Ireland, the Netherlands,
Spain, Switzerland, and the United Kingdom, as well as
Israel. In this analysis, we excluded all individuals who
were of Israeli or Spanish descent because of known differ-
ences in ancestral backgrounds for these individuals,
making the total number of people that we used in this
study 695 parent-offspring trios. More clinical information
about the sample can be found elsewhere.20 Genotyping
was performed by Perlegen Sciences with the Perlegen plat-
form. The Perlegen array has 600,000 tagging SNPs
designed to be in high linkage disequilibrium with un-
typed SNPs for the three HapMap populations. After the
data cleaning and quality control procedures, 429,981
autosomal SNPs were available for analytic use. More0.4 0.45 0.5
ected  Control 
 Case: 1 Selected 
Figure 3. Power Simulations Comparing
the Method Proposed Here to the Stan-
dard TDT and Case-Control Analyses
while Using Selected Controls
This ﬁgure depicts the results of power
simulations in which we used 3000 pro-
bands and compared the standard TDT
and case-control methods to the new
screening method we propose in this
manuscript. In this example, we assume
that the control individuals are selected
for the disease of interest and that there
is a 1:1 matching of cases to control
individuals.
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Figure 4. Power Simulations Comparing
the Method Proposed Here to Standard
TDT and Case-Control Analyses with
a 1:2 Ratio of Cases to Selected Controls
This ﬁgure depicts the results of power
simulations in which we used 3000 pro-
bands and compared the standard TDT
and case-control methods to the new
screening method we propose in this
manuscript. In this example, we assume
that the control individuals are selected
for the disease of interest and that there
is a 1:2 matching of cases to control
individuals.details can be found elsewhere.20 All of the procedures to
collect the IMAGE data were in accordance with the ethical
standards of the responsible committee on human experi-
mentation at each institution.
We obtained 1595 individuals that were a part of the
Psoriasis study, including 676 control individuals and 919
psoriasis cases, from the dbGaP database (accession num-
ber phs000019.v1.p1).21 The institutional review boards
at the respective institutions approved these studies. These
individuals comprised the control sample that was used in
this analysis. In order to minimize problems with popula-
tion stratiﬁcation, we used EIGENSTRAT to identify indi-
viduals with ancestral backgrounds that are not representa-
tive of the ADHD individuals. We identiﬁed 35,836 SNPs
that had minimal linkage disequilibrium (r2 < 0.01) to
use in EIGENSTRAT. We used ﬁve iterations of subject
removal in which individuals were removed if they were
greater then six standard deviations from the mean of
any of the top ten axes of variation. This resulted in 138
controls and 9 ADHD individuals being removed from
the analysis. After we identiﬁed a group of ADHD individ-
uals and properly matched control individuals, we used
the proposed statistical test to identify genetic associations
for ADHD. We also evaluated the quantile-quantile plot to
verify that the p values did not deviate signiﬁcantly from
what was expected.
The newmethod was applied to the IMAGE sample, and
the top 20 associated SNPs are listed in Table 1. Two of the
associations are in genes that have been linked with ADHD
previously. rs2919435 had an uncorrected association
p value of 1.853 105. This SNP is located in the serotonin
receptor 5A (HTR5A [MIM 601305]), which has been
studied previously in relation to ADHDwith negative ﬁnd-
ings.22 rs1477941 had an association p value of 5.07 3
105. This SNP is located on the GNAL (MIM 139312)
and is also among the top associated SNPs that has been
previously studied with regard to ADHD.23,24 Both animalThe American Journal of Humastudies and human studies for ADHD
have been performed on GNAL previ-
ously. GNAL was signiﬁcantly altered
in both the spontaneously hyperten-
sive rats and the PCB-exposed Sprague
Dawley rats that mimic ADHD behav-iors.24 Previous genetic associations with ADHD were
observed in this gene.23 Table 1 demonstrates that,
although many of the associations identiﬁed with the
new screening method are also identiﬁed with the classical
TDT, the SNPs with the strongest genetic associations
change. Therefore, if a percentage of SNPs are to be fol-
lowed up, the lists of SNPs that are carried forward would
be different for the two methods. Knowing that the new
screening method is more powerful, it is clearly best to
select the SNPs with the strongest associations via the
new method.
After the genetic associations for ADHD were identiﬁed
from the IMAGE sample, we used an in silico population
to replicate the ﬁndings. Details about this sample can be
foundelsewhere (E.Mick,personalcommunication).Brieﬂy,
parent-offspring trios were ascertained at Massachusetts
General Hospital, Washington University at St. Louis, and
University of California at Los Angeles (UCLA), and this
study is called PUWMa (Pﬁzer-UCLA-Washington Univer-
sity at St. Louis-Massachusetts General Hospital multisite
GWAS).Childrenwere 6–17years of age at initial assessment
and met criteria for DSM-IV-TR ADHD. Genomic DNA
samples from the Massachusetts General Hospital and
WashingtonUniversity at St. Louiswere genotypedwith the
Illumina Human1M BeadChip, whereas the UCLA samples
were genotyped with the Illumina Human1M-Duo array.
Genotyping calls were generated and then merged into a
single ﬁle. After applying all data-cleaning and quality-
control ﬁlters, there were 835,136 SNPs in 735 ADHD trios
from 732 families. All of the procedures to collect this
replication population were in accordance with the ethical
standards of the responsible committee on human experi-
mentation at each institution.
There were 173,675 common SNPs that were genotyped
in both IMAGE and the replication population. We identi-
ﬁed the association p values that were less than 0.05 in the
IMAGE sample (20,297 SNPs) and merged the associationn Genetics 86, 573–580, April 9, 2010 577
Table 1. Top Association Findings for ADHD in the IMAGE Population
SNP Location Gene MAF FBAT P Value Case-Control P Value New Screen P Value
rs12972735 19 NA 0.38 0.0010 2.06E-05 1.9E-07
rs925910 2 NA 0.48 0.0004 0.00123 3.03E-06
rs192770 3 NA 0.35 0.0007 0.00066688 3.13E-06
rs9459502 6 NA 0.18 0.0022 0.000527839 7.49E-06
rs829417 1 RAP1GA1 (MIM 600278) 0.30 0.0013 0.001130348 9.30E-06
rs1378945 4 KIAA0746 (MIM 100174136) 0.28 3.22E-05 0.031866027 1.76E-05
rs16889099 4 NA 0.07 3.52E-05 0.03057089 1.78E-05
rs7589522 2 FIGN (MIM 605295) 0.28 4.75E-05 0.026842544 2.16E-05
rs2919435 7 HTR5A (MIM 601305) 0.40 6.98E-05 0.02558088 1.86E-05
rs7743622 6 MOXD1 (MIM 609000) 0.43 0.00092 0.003784992 2.33E-05
rs12686281 9 NA 0.09 5.33E-05 0.036737594 3.10E-05
rs16985637 22 TRIOBP (MIM 609761) 0.06 0.00033 0.012050178 3.11E-05
rs470705 2 NA 0.35 0.01408204 0.000265207 3.14E-05
rs2082412 5 UBLCP1 (MIM 609867) 0.20 0.031522535 7.98E-05 3.38E-05
rs7557548 2 NA 0.22 0.00689115 0.000713226 3.21E-05
rs1585804 17 C17orf54 0.30 0.00928631 0.000566461 3.65E-05
rs1026942 4 NA 0.13 0.001519208 0.004341154 3.88E-05
rs2915806 5 SH3TC2 (MIM 608206) 0.41 0.001822735 0.003700023 3.91E-05
rs1335706 10 NA 0.38 0.00063446 0.009405834 4.07E-05
rs1477941 18 GNAL (MIM 139312) 0.10 0.003568628 0.002502729 5.07E-05
This table lists the top SNPs associated with ADHD that were identified by using ADHD individuals from the IMAGE sample and unselected controls from the freely
available psoriasis sample. The association p values are listed from lowest to highest along with relevant information about the SNP, including the chromosomal
location, whether it lies within a gene, the minor allele frequency, and the FBAT and case-control p values. NA denotes not available.p values at these SNPs with the replication population,
resulting in 8,992 genotyped SNPs. Table 2 lists the SNPs
with the 20 lowest association p values in the PUWMa
sample, among those selected from the IMAGE sample.
rs220597 also had a nominal association with ADHD in
the IMAGE (p ¼ 0.037) sample and was among the most
strongly associated SNPs in the replication population
(p¼ 0.0027). This SNP is in the glutamate receptor subunit
gene, has been evaluated previously as a candidate gene,
and has been shown to be associated with ADHD.25,26
Among the SNPs that were evaluated via the new
screening methodology, we were able to identify three
SNPs in candidate genes that were identiﬁed previously
as ADHD candidate genes. Although none of the genetic
associations achieved genome-wide signiﬁcance, the fact
that three of these SNPs are in genes that were previously
identiﬁed for ADHD demonstrate the promise of this
new methodology.
In this manuscript, we propose a new testing method for
parent-offspring trios in which researchers can take advan-
tage of the readily available control genotypes by perform-
ing an analysis that combines both FBAT and case-control
analyses. This method is widely applicable because it can
be extended to any situation in which both parent-578 The American Journal of Human Genetics 86, 573–580, April 9, 2offspring trios and case-control data are available. This
method also easily extends to the case in which there are
large nuclear families. By continuing to parse the genetic
information into the within and between components,
a family-based association test and the case-control anal-
ysis can be performed separately and then combined,
similar to the case of a parent-offspring trio. In such an
analysis, the parental information is replaced by the sufﬁ-
cient statistic by Rabinowitz and Laird,9 and the correla-
tion among offspring in the same family can be taken
into account by conditional logistic regression. Further-
more, a similar approach can be used for quantitative
phenotypes as well.
We have found that this analysis strategy has impressive
improvements in power compared with an FBAT alone.
In addition, thismethodology consistently hasmore power
thana case-control analysis of the same sample size. In addi-
tion to improvements in power, this methodology is more
robust against population stratiﬁcation because it does
not rely on large sample theory. Therefore, the ﬁndings
are more robust against population stratiﬁcation when
compared with standard methodologies. Despite this, it is
still important to make sure that the control individuals
are well matched to the cases by using some type of010
Table 2. Top Replication Association P Values in the PUWMa Replication Sample
SNP Location Gene MAF IMAGE New Screen P Value Replication P Value
rs4369599 15 NA 0.245 0.017 0.00033
rs200654 20 TSHZ2 (MIM 128553) 0.432 0.048 0.00082
rs931671 17 NDEL1 (MIM 607538) 0.382 0.034 0.00095
rs4257183 15 NA 0.123 0.015 0.00113
rs7947031 11 NA 0.172 0.025 0.00170
rs4234306 3 NA 0.470 0.009 0.00188
rs16904936 8 ST3GAL1 (MIM 607187) 0.025 0.031 0.00189
rs11706690 3 CHL1 (MIM 607416) 0.356 0.001 0.00204
rs9912168 17 NA 0.335 0.009 0.00209
rs2088108 1 NA 0.140 0.040 0.00239
rs9644708 8 TNKS (MIM 603303) 0.203 0.030 0.00255
rs2255672 18 MRO (MIM 608080) 0.272 0.026 0.00261
rs220597 12 GRIN2B (MIM 138252) 0.348 0.037 0.00269
rs1661281 10 ANKRD22 (MIM 52024) 0.305 0.043 0.00270
rs1504508 18 NA 0.245 0.025 0.00291
rs10109988 8 NA 0.276 0.038 0.00296
rs17829444 14 RAD51L1 (MIM 602948) 0.201 0.029 0.0031
rs210837 17 NA 0.075 0.045 0.0031
rs1895699 2 NA 0.238 0.049 0.0031
rs2149698 13 NA 0.406 0.020 0.0033
This table lists the SNPs with the strongest genetic associations in the PUWMa replication sample. Note that the genotyping platforms for the initial and replication
samples were different, and as such there were a substantial number of SNPs that were dropped from this comparison. The replication association p values are
listed from lowest to highest along with relevant information about the SNP, including the chromosomal location, whether it lies within a gene, the minor allele
frequency, and the initial IMAGE new screen p values. NA denotes not available.population stratiﬁcation correction, which can be per-
formed with one of several programs.18,27 By incorporating
additional control individuals, this approach has great
promise to identify genetic variants for parent-offspring
trios that are not identiﬁed with the trios only.Acknowledgments
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